5 completed, 3 not yet recruiting, 3 unknown, 1 enrolling by invitation. 7 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Unknown 2 |
Follow EGFR Mutation: new trials by email Literature Review of EGFR Mutation trials Research Report on EGFR Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study Furmonertinib, carboplatin, pemetrexed - Non-small Cell Lung Cancer (NSCLC), Brain Metastases | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-01-01 | 2026-01-26 |
| Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance Oncogene-addicted Non Small Cell Lung Cancer, EGFR Mutation | Enrolling by invitation | Chang Gung Memorial Hospital | 40 | 2025-09-01 | 2026-03-17 | |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Combination therapy prospective cohort - Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Not yet recruiting | Qiming Wang | 100 | 2025-05-15 | 2025-05-14 |
| A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants BAY2927088, Midazolam - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-04-17 | 2024-07-03 |
| A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants BAY2927088, Itraconazole, Carbamazepine - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 30 | 2024-04-10 | 2024-06-20 |
| A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants BAY2927088, Esomeprazole, Food - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 21 | 2024-03-29 | 2024-07-05 |
| A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants BAY2927088, Dabigatran etexilate, Rosuvastatin - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-03-25 | 2024-07-05 |
| A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants BAY2927088 coated tablet 10 mg, [14C]-BAY2927088 solution for infusion, [14C]-BAY2927088 oral solution - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 8 | 2024-01-25 | 2024-06-28 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2 - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Recruiting | Bayer | 430 | 2021-10-25 | 2026-10-21 |
| Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation gefitinib, Berberine - Lung Adenocarcinoma, EGFR Mutation | Phase 2 | Unknown | Fujian Cancer Hospital | 50 | 2018-06-05 | 2018-04-03 |
| Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy - Non-small Cell Lung Cancer, Brain Metastases | Phase 3 | Unknown | Sun Yat-sen University | 160 | 2016-01-01 | 2022-03-08 |
| Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC Erlotinib - NSCLC, EGFR Mutation | Phase 3 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 220 | 2013-08-01 | 2015-02-12 |
Carcinoma, Non-Small-Cell Lung (5) · Brain Neoplasms (2) · Adenocarcinoma of Lung (1) · Central Nervous System Neoplasms (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1)
Neoplasms (7) · Neoplasms by Site (7) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Lung Neoplasms (5) · Respiratory Tract Diseases (5) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Central Nervous System Neoplasms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Adenocarcinoma (1)
Gefitinib (2) · Pemetrexed (2) · Berberine (1) · Carbamazepine (1) · Carboplatin (1) · Dabigatran (1) · Erlotinib Hydrochloride (1) · Esomeprazole (1) · Food (1) · Itraconazole (1) · Midazolam (1) · Platinum (1) · Rosuvastatin Calcium (1) · aflutinib (1) · osimertinib (1)
Bayer (6) · Beijing Pearl Biotechnology Limited Liability Company (1) · Chang Gung Memorial Hospital (1) · Fujian Cancer Hospital (1) · Qiming Wang (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (5) · United States (5) · Netherlands (2) · Taiwan (2) · Belgium (1) · Brazil (1) · France (1) · Hong Kong (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Portugal (1) · Singapore (1) · South Korea (1)
Cheng Huang, MD. (1)
PMID 28665143, PMID 36753281, PMID 41104928
2023 (1)